B
Bull
Bull · 25%MEIP
$8.39
シナリオ価格
$3.070
+0.320 (+10.43%)終値時点
Loading chart…
- High
- 3.250
- Open
- 2.890
- VWAP
- 3.06
- Vol
- 4.03M
- Mkt Cap
- 19.66M
- Low
- 2.850
- Amount
- 12.33M
- EV/EBITDA, TTM
- 0.00
Lite Strategy, Inc., formerly MEI Pharma, Inc., is a Litecoin treasury company. The Company accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. It is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia.
Analyst Ratings (3)
Hold
1 Buy
2 Hold
0 Sell
Current: 3.07
安値
—
平均
—
高値
—
Laidlaw & Co.
Hold
—
2024-07-23
Laidlaw & Co.
2024-07-23
目標株価
—
Hold
Stifel
Hold
$7
2024-04-12
Stifel
2024-04-12
目標株価
$7
Hold
Stifel
Hold
$7
2024-02-14
Stifel
2024-02-14
目標株価
$7
Hold
Stifel
Hold
$9
2023-09-27
Stifel
2023-09-27
目標株価
$9
Hold
Brookline Capital
Strong Buy
$80
2023-05-23
Brookline Capital
2023-05-23
目標株価
$80
Strong Buy
バリュエーション指標
The current forward P/E ratio for MEI Pharma Inc (MEIP) is -0.83, compared to its 5-year average forward P/E of -1.09.
Alphio AI Price Scenarios for MEIP
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
イベントタイムライン
ニュース
4.509-10NewsfilterMEI Pharma, Inc. Changes Name to Lite Strategy, Inc. and Introduces New NASDAQ Ticker 'LITS'
4.509-08BenzingaRobinhood Shares Surge Over 7%; Check Out 20 Stocks Making Moves in Premarket Trading
4.508-05BenzingaMEI Pharma Chooses Not Bitcoin, Not Ethereum, But Litecoin As Treasury Asset
4.507-21BenzingaUS Stocks Likely To Open Higher Despite Trump Administration's 'Hard Deadline' Warning For Tariffs — Verizon, Domino's Pizza Earnings In Focus
8.507-18BenzingaWhy Is MEI Pharma Stock Soaring On Friday?
MEIP FAQ — answered by Alphio AI
Lite Strategy, Inc., formerly MEI Pharma, Inc., is a Litecoin treasury company. The Company accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. It is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
3 analysts cover MEIP: 1 rate it Buy, 2 Hold and 0 Sell.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。